INAB IN8BIO INC

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.

A high-definition video webcast of the presentation will be available the following day on the Company's website /news-events/events-presentations, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: and on Channelchek the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit  

Investors and Corporate Contacts:

Glenn Schulman, PharmD, MPH

203.494.7411

Patrick McCall, CFO

IN8bio, Inc

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
02/12/2024

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio to Present at TD Cowen 46th Annual Health Care Conference NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, wil...

February 24, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating ...

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beg...

February 9, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at Upcoming Investor and Scientific Conferences in F...

IN8bio to Present at Upcoming Investor and Scientific Conferences in February NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual IO360° Conferenc...

February 3, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and D...

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to onl...

January 12, 2026 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Announces Pricing of Private Placement of up to $40.2 Million t...

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage...

December 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch